| A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice D Zhang, P Baldwin, AS Leal, S Carapellucci, S Sridhar, KT Liby Theranostics 9 (21), 6224, 2019 | 47 | 2019 |
| Identification of an unfavorable immune signature in advanced lung tumors from Nrf2-deficient mice D Zhang, J Rennhack, ER Andrechek, CE Rockwell, KT Liby Antioxidants & redox signaling 29 (16), 1535-1552, 2018 | 38 | 2018 |
| Sustained release talazoparib implants for localized treatment of BRCA1-deficient breast cancer JE Belz, R Kumar, P Baldwin, NC Ojo, AS Leal, DB Royce, D Zhang, ... Theranostics 7 (17), 4340, 2017 | 30 | 2017 |
| Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762 D Zhang, AS Leal, S Carapellucci, K Zydeck, MB Sporn, KT Liby Cancer Prevention Research 11 (3), 143-156, 2018 | 23 | 2018 |
| A novel Nrf2 pathway inhibitor sensitizes keap1-mutant lung cancer cells to chemotherapy D Zhang, Z Hou, KE Aldrich, L Lockwood, AL Odom, KT Liby Molecular cancer therapeutics 20 (9), 1692-1701, 2021 | 22 | 2021 |
| Activation of liver X receptor inhibits the development of pulmonary carcinomas induced by 3-methylcholanthrene and butylated hydroxytoluene in BALB/c mice Q Wang, L Sun, X Yang, X Ma, Q Li, Y Chen, Y Liu, D Zhang, X Li, ... Scientific Reports 6 (1), 27295, 2016 | 22 | 2016 |
| Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models AS Leal, K Zydeck, S Carapellucci, LA Reich, D Zhang, JA Moerland, ... NPJ Breast Cancer 5 (1), 39, 2019 | 20 | 2019 |
| Potential therapeutic uses of rexinoids AS Leal, LA Reich, JA Moerland, D Zhang, KT Liby Advances in Pharmacology 91, 141-183, 2021 | 15 | 2021 |
| Testing novel pyrimidinyl rexinoids: a new paradigm for evaluating rexinoids for cancer prevention D Zhang, AS Leal, S Carapellucci, PH Shahani, JS Bhogal, S Ibrahim, ... Cancer Prevention Research 12 (4), 211-224, 2019 | 15 | 2019 |
| The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer JA Moerland, D Zhang, LA Reich, S Carapellucci, B Lockwood, AS Leal, ... Scientific Reports 10 (1), 22244, 2020 | 11 | 2020 |
| The RXR agonist MSU42011 Is effective for the treatment of preclinical HER2+ breast cancer and Kras-driven lung cancer AS Leal, JA Moerland, D Zhang, S Carapellucci, B Lockwood, ... Cancers 13 (19), 5004, 2021 | 10 | 2021 |
| The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer LA Reich, JA Moerland, AS Leal, D Zhang, S Carapellucci, B Lockwood, ... Scientific reports 12 (1), 293, 2022 | 8 | 2022 |
| Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice D Zhang, B Singh, J Moerland, O Mitchell, L Lockwood, S Carapellucci, ... Scientific Reports 11 (1), 1234, 2021 | 6 | 2021 |
| Exploring structural effects in a new class of NRF2 inhibitors Z Hou, L Lockwood, D Zhang, CJ Occhiuto, L Mo, KE Aldrich, HE Stoub, ... RSC Medicinal Chemistry 14 (1), 74-84, 2023 | 2 | 2023 |
| Profiling changes in metabolism and the immune microenvironment in lung tumorigenesis D Zhang, AS Leal, FA Rous, KT Liby Annals of Translational Medicine 7 (Suppl 3), 2019 | 2 | 2019 |
| Comparison of the rexinoids Bexarotene and Pyrimidine‐Bexarotene in a preclinical model of lung carcinogenesis D Zhang, AS Leal, S Carapellucci, K Zydeck, N Chaaban, MB Sporn, ... The FASEB Journal 31, 671.16-671.16, 2017 | 1 | 2017 |
| The novel rexinoid V-125 reduces tumor growth in the MMTV-Neu model of breast cancer and the A/J model of lung cancer via immunomodulation L Reich, J Moerland, AS Leal, D Zhang, S Carapellucci, CE Wagner, ... Cancer Research 82 (12_Supplement), 1118-1118, 2022 | | 2022 |
| Immunomodulation by Small Molecules for Prevention or Treatment of Cancer D Zhang Michigan State University, 2020 | | 2020 |
